[Clinical evaluation of ceftazidime monotherapy for infections complicated with hematological disorders].
Fifty patients with infections associated with hematological disorders were treated with ceftazidime (CAZ). Among them 44 cases were evaluable, including 21 with acute leukemia, 17 with malignant lymphoma, and 6 with other hematological disorders. Excellent responses were observed in 15 patients (34.1%) and good responses in 15 (34.1%), with an overall efficacy rate of 68.2%. The efficacy rate among sepsis and suspected sepsis cases was 67.6%. This treatment was also effective in 7 of 10 cases in which neutrophil counts were less than 500/mm3 through the course of administration. Laboratory abnormalities included mild eosinophilia in 1 case, slight elevation of GOT in 1 case and slight elevation of GPT in 1 case. These results suggest that CAZ is an effective and safe antibiotics for the treatment of infections in patients with hematological disorders.
Kuzuyama
Y
Y
Third Department of Internal Medicine, Kyoto Prefectural University of Medicine.
Tsuda
S
S
Seriu
T
T
Nakai
H
H
Murakami
T
T
Takashima
T
T
Takahashi
Y
Y
Tanaka
S
S
Nakagawa
H
H
Nishigaki
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002442:Ceftazidime / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007938:Leukemia / Q000150:complications* / Q000276:immunology; D007958:Leukocyte Count; D008223:Lymphoma / Q000150:complications* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009504:Neutrophils; D011014:Pneumonia / Q000188:drug therapy*; D018805:Sepsis / Q000188:drug therapy*
D002442:Ceftazidime